Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Esther Mena

Showing results (61-70 of 119) with videos related to

Pageof 12
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 14, 2015
Comprehensive radionuclide esophagogastrointestinal transit study: methodology, reference values, and initial clinical experienceAlexander J Antoniou, Shreya Raja, Riham El-Khouli, et al.
Clinical Nuclear Medicine|August 22, 2014
A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapyEsther Mena, Maria Liza Lindenberg, Baris I Turkbey, et al.
Frontiers in Oncology|May 8, 2024
Salivary excretion of systemically injected [<sup>18</sup>F]DCFPyL in prostate cancer patients undergoing PSMA scansBruna Fernandes, Jyoti Roy, Falguni Basuli, et al.
American Journal of Nuclear Medicine and Molecular Imaging|September 16, 2017
Dosimetry and first human experience with <sup>89</sup>Zr-panitumumabLiza Lindenberg, Stephen Adler, Ismail B Turkbey, et al.
Oncotarget|March 11, 2015
Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imagingLiza Lindenberg, Anish Thomas, Stephen Adler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 4, 2018
Biodistribution, Tumor Detection, and Radiation Dosimetry of <sup>18</sup>F-5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine in Solid TumorsColin R Young, Stephen Adler, Janet F Eary, et al.
Academic Radiology|September 29, 2023
Predicting <sup>18</sup>F-DCFPyL-PET/CT Scan Positivity in Prostate Cancer Patients with Biochemical RecurrenceKaterina H Lee, Esther Mena, Joanna Shih, et al.
BJR Case Reports|September 14, 2020
Local failure after definitive radiation treatment of lymph-node positive prostate cancer: supporting the use of novel imaging techniques to personalize treatment optionsAvinash R Chaurasia, Clayton P Smith, Peter Pinto, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 29, 2014
[¹⁸F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrinsEsther Mena, Rikard Owenius, Baris Turkbey, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 2017
Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point <sup>18</sup>F-FDG PET/CT Imaging in Patients with Advanced MelanomaSteve Y Cho, Evan J Lipson, Hyung-Jun Im, et al.
Pageof 12

Showing results (61-70 of 119) with videos related to

Sort By:
Pageof 12
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 14, 2015
Comprehensive radionuclide esophagogastrointestinal transit study: methodology, reference values, and initial clinical experienceAlexander J Antoniou, Shreya Raja, Riham El-Khouli, et al.
Clinical Nuclear Medicine|August 22, 2014
A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapyEsther Mena, Maria Liza Lindenberg, Baris I Turkbey, et al.
Frontiers in Oncology|May 8, 2024
Salivary excretion of systemically injected [<sup>18</sup>F]DCFPyL in prostate cancer patients undergoing PSMA scansBruna Fernandes, Jyoti Roy, Falguni Basuli, et al.
American Journal of Nuclear Medicine and Molecular Imaging|September 16, 2017
Dosimetry and first human experience with <sup>89</sup>Zr-panitumumabLiza Lindenberg, Stephen Adler, Ismail B Turkbey, et al.
Oncotarget|March 11, 2015
Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imagingLiza Lindenberg, Anish Thomas, Stephen Adler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 4, 2018
Biodistribution, Tumor Detection, and Radiation Dosimetry of <sup>18</sup>F-5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine in Solid TumorsColin R Young, Stephen Adler, Janet F Eary, et al.
Academic Radiology|September 29, 2023
Predicting <sup>18</sup>F-DCFPyL-PET/CT Scan Positivity in Prostate Cancer Patients with Biochemical RecurrenceKaterina H Lee, Esther Mena, Joanna Shih, et al.
BJR Case Reports|September 14, 2020
Local failure after definitive radiation treatment of lymph-node positive prostate cancer: supporting the use of novel imaging techniques to personalize treatment optionsAvinash R Chaurasia, Clayton P Smith, Peter Pinto, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 29, 2014
[¹⁸F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrinsEsther Mena, Rikard Owenius, Baris Turkbey, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 2017
Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point <sup>18</sup>F-FDG PET/CT Imaging in Patients with Advanced MelanomaSteve Y Cho, Evan J Lipson, Hyung-Jun Im, et al.
Pageof 12